17,261 trials
Nontuberculous Mycobacterium Infection
Primary: Percent Patients With Negative Sputum Culture — 40 percentage of participants
Primary Biliary Cholangitis
Primary: Percentage of Participants With At Least a 20% Reduction in Alkaline Phosphatase (ALP) or Normalization of ALP at Week 12 Compared to Baseline — 45.2; 46.4; 11.1…
Endothelial Dysfunction
Primary: Area Under the Curve (AUC0-12hrs) of Plasma BH4 Concentration — 633; 993 nM*hr — p=<0.001
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Major Pathologic Response (MPR) — 20.3 percentage of participants — p=<.0001
Stable Coronary Artery Disease
Primary: Number of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation — 102; 103; 18 Count of participants (i.e., responders)…
Active Psoriatic Arthritis
Primary: Percentage of Participants Achieving the American College of Rheumatology (ACR) 20 Response at Week 16 — 31.8; 52.9; 62.7 Percent of Participants — p=<0.001
Modified Release Oral Formulation · Left Ventricular Systolic Dysfunction · Chronic Heart Failure
Primary: Dose Escalation Phase: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7) — 193; 201; 171; 492 ng/mL
Avian Influenza · Influenza Immunisation
Primary: Geometric Mean Titers (GMT) of Serum Hemagglutinin Inhibition (HAI) Antibodies — 23.3; 19.9; 24.2; 6.0 titer
Stage IIIA Non-small Cell Lung Cancer
Primary: Number of Participants Deemed Feasible to Receive Intervention — 21 Participants
Malignant Adrenal Gland Pheochromocytoma · Malignant Paraganglioma · Metastatic Adrenal Gland Pheochromocytoma
Primary: Confirmed Tumor Response Rate — 1.0 participants
Thyroid Gland Anaplastic Carcinoma
Primary: (Phase II) Overall Survival — 37.1; 29.0 percentage of participants — p=0.2831
Lichen Planus
Primary: Change in Oral Sensitivity — -4.5; -6.0 score on a scale
Adult Women · Metastatic Breast Cancer · Estrogen Receptor Positive
Primary: Change in Serum 25(OH)D — 32 ng/ml — p=<0.01
Hormone-Resistant Prostate Cancer · Metastatic Prostate Carcinoma · Recurrent Prostate Carcinoma
Primary: Change in Tissue Testosterone and Dihydrotestosterone — 0.156 pg/mg
Castration Resistant Prostate Cancer
Primary: Clinical Benefit of NRX 194204 in Men With Castration- and Taxane-resistant Metastatic Prostate Cancer — 19 Participants